Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors

被引：0
|
作者：
Sharma, Sunil
Starodub, Alexander
Xu, Nong
Chaudhry, Arvind
Sun, Meili
Pelster, Meredith
Fu, Yinjia
Zhang, Xinyu
Huang, Zhao
Liu, Wenyu
Hsu, Karl
机构：
[1] Honor Hlth, Scottsdale, AZ USA
[2] Parkview Canc Inst, Parkview Physician Grp, Cincinnati, OH USA
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China
[4] Summit Canc Centers, Spokane Valley, WA USA
[5] Jinan Cent Hosp, Jinan, Peoples R China
[6] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[7] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
[8] Zai Lab Shanghai Co Ltd, R&D Dept, Shanghai, Peoples R China
[9] Zai Lab US LLC, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2537
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
    Reid, Tony
    Oronsky, Bryan
    Scicinski, Jan
    Scribner, Curt L.
    Knox, Susan J.
    Ning, Shoucheng
    Peehl, Donna M.
    Korn, Ron
    Stirn, Meaghan
    Carter, Corey A.
    Oronsky, Arnold
    Taylor, Michael J.
    Fitch, William L.
    Cabrales, Pedro
    Kim, Michelle M.
    Burris, Howard A.
    Lao, Christopher D.
    Abrouk, Nacer E. D.
    Fanger, Gary R.
    Infante, Jeffrey R.
    LANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142
  • [22] First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors
    Wang, Yakun
    Gong, Jifang
    Lin, Rongbo
    Zhao, Shen
    Wang, Jufeng
    Wang, Qianli
    Zhang, Yanqiao
    Su, Dan
    Zhang, Jingdong
    Dong, Qian
    Lin, Ling
    Tian, Wen
    Chen, Ying
    Yang, Yang
    Zhang, Xueyuan
    Wan, Xuechao
    Gao, Jinfeng
    An, Na
    Jansen, Valerie Malyvanh
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.
    Zhou, Fei
    Li, Wei
    Chen, Yu
    Lin, Jing
    Chen, Ling
    Zhang, Huishan
    Dong, Xiaorong
    Tong, Fan
    Zhang, Ruiguang
    Yin, Yongmei
    Liang, Yan
    Yang, Nong
    Hu, Sheng
    Zhuang, Wei
    Li, Tao
    Cai, Shengli
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
    Meng, Yanchun
    Zhang, Jian
    Zhao, Chuanhua
    Cheng, Ying
    Zhu, Liming
    Song, Zhengbo
    Xu, Nong
    Wang, Zhen
    Wang, Yanping
    Du, Yiqun
    Jing, Deqiang
    Chen, Dinglu
    Qu, Qiaofeng
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] A phase 1b, open-label, dose escalation and expansion study of demcizumab plus pembrolizumab in patients with locally advanced or metastatic solid tumors
    Johnson, Melissa
    Rasco, Drew
    Schneider, Brian
    Shu, Catherine
    Jotte, Robert
    Parmer, Hema
    Stagg, Robert
    Lopez, Juanita
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [26] Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
    Moore, Kathleen N.
    Bendell, Johanna C.
    Olszanski, Anthony J.
    Desai, Madhuri
    Jansen, Mendel
    Scheyer, Richard David
    Senaldi, Giorgio
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR 3 CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
    Weickhardt, A. J.
    Frentzas, S.
    Lemech, C.
    Srimani, J.
    Yin, J.
    Trepicchio, W. L.
    Gorgun, C.
    Kichenadasse, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S492 - S492
  • [28] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [29] First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Piha-Paul, Sarina A.
    Geva, Ravit
    Tan, Tira J.
    Lim, Darren Wt
    Hierro, Cinta
    Doi, Toshikiko
    Rahma, Osama
    Lesokhin, Alexander
    Luke, Jason John
    Otero, Javier
    Nardi, Lisa
    Singh, Angad
    Xyrafas, Alexandros
    Chen, Xinhui
    Mataraza, Jennifer
    Bedard, Philippe L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (08)
  • [30] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
    Mettu, Niharika B.
    Ulahannan, Susanna, V
    Bendell, Johanna C.
    Garrido-Laguna, Ignacio
    Strickler, John H.
    Moore, Kathleen N.
    Stagg, Robert
    Kapoun, Ann M.
    Faoro, Leonardo
    Sharma, Sunil
    CLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892
12345